Pipeline-in-a-drug, page-139

First 139 Last

Share
Profile

Follow
Anydaynow

1,886 Posts.

469

05/06/24

06:32

Post #: 74166190
Share

Originally posted by giarc63: ↑

For Acadia to develop trofinetide for an indication just to preclude Neuren from developing NNZ2591 for the same indication is absurd.

The cost alone for Acadia to do that would be phenominal. I am not saying that Acadia does not have the right to progress trofinetide in any indication that it wishes to, but the likelihood of trofinetide to pass all the regulatory requirements is far less than the likelihood that the "superior drug" NNZ2591 would.

The sheer cost of Acadia doing this would drive them out of business.

Acadia is much better suited to progress NNZ2591 for Retts and Fragile-X and I have been waiting for that announcement to drop since the last agreement was signed with Neuren. John keeps saying that decision is totally up to Acadia. I believe also that John does not believe that Acadia would promote trofinetide in any undisclosed indication just to preclude Neuren from doing ii with NNZ2591. The cost alone of doing that should stop Acadia in its tracks.

Once again - the relationship between Acadia and Neuren has been convivial to this date and there is no reason to belive that it will not continue to be so.

The recent back track in the share price for Acadia can be attributed more to its failure with another drug and not to the preformance of Daybue/trofinetide.

Acadia Pharmaceuticals (NASDAQ:ACAD) faced a sharp decline this year after deciding not to proceed with further trials for pimavanserin, a drug aimed at treating schizophrenia, and now its outlook looks bleak or at least unfavorable.

Although the Daybue sales came in the lower ebb of the expected sales - Daybue/Trofinetide continues to serve its purpose for Neuren.

The future for Neuren definitely lies with NNZ2591 and I see no reason for concern as to the ability of NNZ2591 to treat multiple neurological indications. That is the scientific aim for this drug.

I also cannot see that Acadia would ever target an indication just to preclude Neuren from doing so, it cuts against the grain that they would ever consider doing that, let alone be able to afford to do so - in reality. That would be absurd.

Expand

I agree Giarc, just when NEU is seeing blue sky on it’s horizon with nary a cloud in sight HC posters are seeing smoke and mirrors.
FWIW I wouldn’t be surprised to see a takeover of both ACAD and NEU by a much much bigger BP, it would simplify the whole process and give an immediate revenue return in Trof without the need to pay royalties to NEU. IMHO NEU is worth at least x5 the price of ACAD.

NEU Price at posting: $19.02 Sentiment: Buy Disclosure: Held
18 Upvote

0 Great analysis

Reply

Top Stories

Wealth Within: the latest stock tips from Dale Gillham

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

ASM

ASM to push Dubbo REE play towards economical production with A$5M Federal govt grant

A1G

African Gold finds significant 5.5g/t intercept over 65m in Cote d’Ivoire

BM8

Battery Age Minerals gets set to capitalise on critical mineral demand

There are more pages in this discussion • 50 more messages in this thread...

First 139 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $13.01		Change -0.010(0.08%)		Mkt cap ! $1.662B

Open	High	Low	Value	Volume
$13.06	$13.26	$12.81	$5.865M	451.8K

Buyers (Bids)

No.	Vol.	Price($)
4	14541	$13.00

Sellers (Offers)

Price($)	Vol.	No.
$13.02	2438	1

View Market Depth

No.	Vol.	Price($)
4	14541	13.000
1	75	12.990
1	2500	12.960
1	300	12.950
4	3866	12.940

Price($)	Vol.	No.
13.020	2438	1
13.030	867	1
13.040	69	1
13.050	3366	3
13.070	1999	1

Last trade - 16.10pm 15/10/2024 (20 minute delay)

NEU (ASX) Chart

Pipeline-in-a-drug, page-139

Wealth Within: the latest stock tips from Dale Gillham

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

ASM to push Dubbo REE play towards economical production with A$5M Federal govt grant

African Gold finds significant 5.5g/t intercept over 65m in Cote d’Ivoire

Battery Age Minerals gets set to capitalise on critical mineral demand

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Pipeline-in-a-drug, page-139

Top Stories

Wealth Within: the latest stock tips from Dale Gillham

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

ASM to push Dubbo REE play towards economical production with A$5M Federal govt grant

African Gold finds significant 5.5g/t intercept over 65m in Cote d’Ivoire

Battery Age Minerals gets set to capitalise on critical mineral demand

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News